NasdaqGM:LNTHMedical Equipment
The Bull Case For Lantheus (LNTH) Could Change Following SPECT Exit And Neuro Imaging Refocus
Lantheus Holdings has completed the sale of its SPECT business unit and reported progress in neurodegenerative imaging, including past CTAD 2025 data presentations and anticipated 2026 regulatory decisions for new beta-amyloid and tau agents, while planning a reformulated Pylarify launch to address pricing pressures.
This repositioning concentrates capital and management attention on higher-growth imaging platforms, potentially altering how investors view the balance between product...